Neuroleptic malignant syndrome during abrupt reduction of neuroleptic treatment.
Development of neuroleptic malignant syndrome (NMS) following discontinuation of high-dose and high-potency neuroleptic agents is described. This case, although rare and atypical, should alert clinicians to consider the possibility of NMS as a complication of abrupt neuroleptic drug withdrawal. It is suggested that dopaminergic imbalance, as opposed to excessive dopaminergic blockade, may also play a role in the precipitation of NMS.
Spivak
B
B
Gehah Psychiatric Hospital, Beilinson Medical Center, Petah Tiqva, Israel.
Weizman
A
A
Wolovick
L
L
Hermesh
H
H
Tyano
S
S
Munitz
H
H
D000293:Adolescent; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002746:Chlorpromazine / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006220:Haloperidol / Q000009:adverse effects; D006801:Humans; D008297:Male; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology*; D011618:Psychotic Disorders / Q000188:drug therapy*; D013375:Substance Withdrawal Syndrome / Q000209:etiology*; D014282:Trihexyphenidyl / Q000009:adverse effects
D014150:Antipsychotic Agents; D014282:Trihexyphenidyl; D006220:Haloperidol; D002746:Chlorpromazine